During CPHI 2026, held in Milan, MIAT presented the expansion of its portfolio with a new range of raw materials dedicated to the medical aesthetics sector.
This development responds to the growing demand for high-performance dermocosmetic and medical-aesthetic solutions, combining high quality standards with a strong scientific foundation.
Building on more than 50 years of experience in the global market and a long-standing presence in the Hyaluronic Acid sector, MIAT is now expanding its offering with advanced pharmaceutical- and medical-grade bioactives.
Among the solutions distributed by MIAT:
- Injectable- and Medical-Grade Hyaluronic Acid (sterile and cross-linked grades): high-quality solutions produced through microbial fermentation and advanced cross-linking technologies, designed for dermal fillers, revitalizing treatments and medical-aesthetic devices.
- Innovative bioactives and polymers: including recombinant human collagen, calcium hydroxyapatite and cross-linked matrix products developed for next-generation regenerative and anti-aging applications.
Through strategic partnerships, MIAT provides customers and formulators with a portfolio combining high purity, compliance with stringent international regulatory standards and continuous biotechnological innovation.
CPHI Milan 2026 once again proved to be an important opportunity to strengthen business relationships, share technical expertise and explore the evolving frontiers of medical aesthetics and skin health.
